Wednesday, December 21, 2016 10:13:27 PM
Could not resist - Bought 50K shares today, my last batch for a total of 300K shares.
I believe that patience will pay. In another 3 months we should have data on 150 mg 200mg and 300mg viread. Wont be surprised if we have really great data at 150mg that may have management decide not to go ahead with 200mg data. Even if they do go ahead, then by end of 200mg data, they should have 300mg viread data for comparison - correct me if i am wrong.
Long term is what I look at - anywhere from 12 to 18 months.
Recent HEPA News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 02:02:26 PM
- Hepion Pharmaceuticals Announces Exercise of Warrants for Approximately $2.0 Million Aggregate Gross Proceeds • GlobeNewswire Inc. • 02/16/2024 01:00:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 08:38:57 PM
- Hepion Pharmaceuticals to Present at NASH-TAG 2024 • GlobeNewswire Inc. • 01/03/2024 10:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/03/2024 09:30:24 PM
- Hepion Pharmaceuticals Announces Restructuring Plan to Enhance Shareholder Value and Management Changes • GlobeNewswire Inc. • 12/07/2023 01:00:00 PM
- Hepion Pharmaceuticals to Present at the 7th Obesity & NASH Drug Development Summit • GlobeNewswire Inc. • 11/28/2023 09:15:00 PM
- Hepion Pharmaceuticals Announces Major Reductions in Liver Stiffness with Rencofilstat Treatment in 17-week Phase 2 Study of Advanced (F3) MASH Liver Disease • GlobeNewswire Inc. • 11/13/2023 09:05:00 PM
- Hepion Pharmaceuticals Schedules Conference Call to Review Additional Efficacy Data from Phase 2 ‘ALTITUDE-NASH’ Liver Function Trial of Rencofilstat • GlobeNewswire Inc. • 11/10/2023 01:50:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/09/2023 05:15:08 AM
- Hepion Pharmaceuticals’ Rencofilstat Demonstrates Anti-Cancer Activity in Hepatitis C-Associated Cancer Model • GlobeNewswire Inc. • 10/25/2023 12:30:00 PM
- Hepion Pharmaceuticals Announces $5.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market under Nasdaq Rules • GlobeNewswire Inc. • 09/29/2023 12:00:00 PM
- Hepion Pharmaceuticals to Participate in 2023 Cantor Global Healthcare Conference • GlobeNewswire Inc. • 09/21/2023 08:05:00 PM
- New Anti-Cancer Opportunities Revealed for Hepion Pharmaceuticals’ Rencofilstat in Cancer Screening Program • GlobeNewswire Inc. • 09/21/2023 12:00:00 PM
- Hepion Pharmaceuticals Discovers Novel Rencofilstat Action in Liver Cancer • GlobeNewswire Inc. • 09/19/2023 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/18/2023 12:00:24 PM
- Rencofilstat Produces Positive Outcomes in Translational Study on Idiopathic Pulmonary Fibrosis • GlobeNewswire Inc. • 09/14/2023 12:45:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/06/2023 08:40:33 PM
- Hepion Pharmaceuticals Announces Management Changes • GlobeNewswire Inc. • 09/06/2023 08:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/24/2023 08:04:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/21/2023 08:41:16 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/21/2023 08:39:46 PM
- Hepion Pharmaceuticals to Present Two Posters at EASL International Liver Congress™ 2023 • GlobeNewswire Inc. • 06/15/2023 08:45:00 PM
- Hepion Pharmaceuticals Announces Passing of Key Safety Milestone in Phase 2b ‘ASCEND-NASH’ Trial of Rencofilstat • GlobeNewswire Inc. • 06/15/2023 12:22:00 PM
- Hepion Pharmaceuticals to Highlight AI-POWR™ at the 2023 CSPS Annual Symposium: The Next Frontiers in Pharmaceutical Sciences • GlobeNewswire Inc. • 05/24/2023 08:45:00 PM
Endexx Corporation (EDXC) Leverages Global Market Trends and Legislative Reforms to Spearhead Growth in the Cannabis and Plant-Based Wellness Sectors • EDXC • Mar 27, 2024 3:01 PM
Applied UV, Inc. Announces Pricing of $2.76 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules • AUVI • Mar 27, 2024 2:51 PM
POET and MultiLane Collaborate to Develop High-Speed Pluggable Transceivers for AI Networks • POET • Mar 27, 2024 10:52 AM
Maybacks Global Entertainment Opens 23 More Stations in Important Major Cities • AHRO • Mar 27, 2024 9:00 AM
NxGen Brands Inc. Forecast to Deliver 140% Growth in Q1 2024 • NXGB • Mar 27, 2024 7:30 AM
Kona Gold Beverages, Inc. Strategic Advancements: Covert LLC Introduces Federally Legal D9 Gummies and Revamps Innovative eCommerce Platform, Propelling Toward $12 Million Annual Revenue Goal • KGKG • Mar 26, 2024 8:30 AM